Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial
Open Access
- 22 February 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 18 (1), 1-6
- https://doi.org/10.1186/s13063-017-1800-3
Abstract
Long-acting bronchodilator monotherapy (long-acting β2-agonist [LABA] or long-acting muscarinic antagonist [LAMA]) is extensively used for treatment of patients with chronic obstructive pulmonary disease (COPD) with mild-to-moderate airflow limitation. However, a substantial number of patients remain symptomatic despite treatment with a single bronchodilator, necessitating a change in therapy. This 12-week, randomized, multicenter, open-label, phase IV study aims to show that the once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μg fixed-dose LABA/LAMA combination results in an improved lung function in symptomatic patients with mild-to-moderate COPD who switch from once-daily tiotropium 18 μg. The study aims to enroll a total of 404 symptomatic patients in Korea with mild-to-moderate COPD who received tiotropium for at least 12 weeks prior to the study initiation. The primary objective of this study is to demonstrate the superiority of IND/GLY over tiotropium in terms of trough forced expiratory volume in 1 second (FEV1) following 12 weeks of treatment. Secondary endpoints include the pre-dose trough FEV1 after 4 weeks of treatment, transition dyspnea index (TDI) total score, COPD assessment test (CAT) total score, and rescue medication use following the 12-week treatment, and safety assessment over the 12-week treatment. This study intends to establish the use of LABA/LAMA combination therapy in symptomatic patients with mild-to-moderate COPD by demonstrating the superiority of IND/GLY over tiotropium monotherapy. ClinicalTrials.gov, NCT02566031 . Registered on 10 August 2015.Keywords
Funding Information
- Novartis Korea Ltd
This publication has 12 references indexed in Scilit:
- Global burden of COPDRespirology, 2015
- Factors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with COPD – subgroup analysis of the Taiwan obstructive lung disease cohortInternational Journal of Chronic Obstructive Pulmonary Disease, 2015
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEuropean Respiratory Journal, 2013
- Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN studyRespiratory Medicine, 2013
- Dual bronchodilation with QVA149versussingle bronchodilator therapy: the SHINE studyEuropean Respiratory Journal, 2013
- Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyThe Lancet Respiratory Medicine, 2013
- The future of combining inhaled drugs for COPDCurrent Opinion in Pharmacology, 2012
- Prevalence of chronic obstructive pulmonary disease in Korea: The fourth Korean National Health and Nutrition Examination Survey, 2008Respirology, 2011
- Disease severity and symptoms among patients receiving monotherapy for COPDPrimary Care Respiratory Journal, 2010
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007